Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies

Blood Adv. 2023 Jun 13;7(11):2459-2462. doi: 10.1182/bloodadvances.2022009475.

Authors

Andres Chang^{1

2}, Jean L Koff¹, Lilin Lai^{2

3

4}, Victor M Orellana-Noia¹, Minal Surati¹, Alyssa M K Leal¹, Madison L Ellis³, Bushra Wali³, Alberto Moreno³, Susanne L Linderman², Colin B O'Leary¹, Pamela B Allen¹, Michael C Churnetski¹, Madhav V Dhodapkar¹, Mehul S Suthar^{2

3}, Jonathon B Cohen¹, Rafi Ahmed²

Affiliations

¹ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
² Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA.
³ Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
⁴ Emory National Primate Research Center, Atlanta, GA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
COVID-19*
Humans
SARS-CoV-2*

Substances

cilgavimab and tixagevimab drug combination
Antibodies, Monoclonal

Supplementary concepts

SARS-CoV-2 variants

Grants and funding